Guide contents
Open in calculatorCompound briefing
Semaglutide is a 31-amino-acid GLP-1 analogue with 94% sequence homology to native GLP-1, modified with a C-18 fatty diacid chain enabling albumin binding and a approximately 7-day half-life. It is the most clinically validated peptide in the GLP-1 class, with extensive Phase 3 data across obesity, type 2 diabetes, cardiovascular, hepatic and neurological research areas.
The research question
Semaglutide is a long-acting incretin-mimetic compound with one of the most mature datasets in this library. Its week-long exposure profile makes titration, gastrointestinal tolerability and changes in body composition central research variables.
Mechanism & research themes
Activates GLP-1R on pancreatic β-cells to enhance glucose-dependent insulin secretion and suppress glucagon, while acting on hypothalamic GLP-1 receptors to reduce appetite and delay gastric emptying.
Mean 14.9–17.4% body weight reduction at 2.4mg/week (STEP trials, 68 weeks)
20% MACE reduction in non-diabetic obese subjects (SELECT, NEJM 2023)
HbA1c reduction of 1.5–2.0% vs placebo (SUSTAIN program)
59% NASH resolution vs 17% placebo (Phase II, NEJM 2021)
Reduced Parkinson's / Alzheimer's incidence signals in GLP-1 RA users
Emerging research into addiction and compulsive-behaviour applications
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Semaglutide has a large randomised trial literature across glycaemic control, weight outcomes and cardiovascular endpoints. That evidence applies to studied formulations and populations, not arbitrary research preparations.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Standard research titration: 0.25mg weekly (weeks 1–4) → 0.5mg (weeks 5–8) → 1.0mg (weeks 9–12) → 1.7mg (weeks 13–16) → 2.4mg weekly maintenance. Subcutaneous (abdomen, thigh or upper arm). Research protocols typically 12–68 weeks.
Reported persistence
approximately 168 hours (approximately 7 days), supporting once-weekly dosing.
Calculator starting point
0.25 mg per reference dose
1 doses per week · 16-week cycle
2 mL default reconstitution volume
Titrate: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, ~4 weeks at each step.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate SemaglutideLaboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 2mL bacteriostatic water for a 2.5mg/mL working concentration. Swirl gently and allow to sit 2–3 minutes; do not shake.
Storage reference
Lyophilised: 2–8°C (stable approximately 36 months frozen); short-term room-temperature use acceptable. Reconstituted: 2–8°C, do not freeze, use within 28 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
GI side effects (nausea, vomiting, diarrhoea, constipation) reported in 40–70% of STEP participants — dose-dependent and a leading driver of discontinuation.
25–39% of total weight lost may be lean mass — concurrent resistance training and adequate protein intake are critical.
FDA gastroparesis warning (2023); dose- and duration-dependent risk of pathologically delayed gastric emptying.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading